Hung-Lun Hsu

Hung-Lun Hsu is a Scientist II currently employed at Voyager Therapeutics, Inc. since April 2024, with prior experience at Frontera Therapeutics and Oxford Biomedica Solutions, focusing on upstream and downstream process development for AAV production. At Oxford Biomedica, responsibilities included performing small-scale and bioreactor AAV production, conducting next-generation sequencing and bioinformatics for plasmid quality control, and enhancing AAV titer through construct design. Previously, at Homology Medicines, Inc., Hung-Lun Hsu contributed to AAV production and virology studies. A postdoctoral associate at the University of Massachusetts Medical School, research involved AAV-based gene therapy and the discovery of capsid variants for improved transduction efficiency. Educational qualifications include a PhD and a Master of Engineering in Chemical Engineering from Cornell University, and a Bachelor of Science from National Taiwan University.